AIM
CBMG

ARK Investment Management’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

ARK Investment Management’s Portfolio CBMG Stock Details CBMG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-71,010
Closed -$1.3M – 248
2020
Q3 		$1.3M Sell
71,010
-530,643
-88% -$8.92M 0.01% 143
2020
Q2 		$9.01M Buy
601,653
+202,021
+51% +$2.89M 0.1% 83
2020
Q1 		$6.32M Sell
399,632
-12,248
-3% -$198K 0.16% 69
2019
Q4 		$6.69M Buy
411,880
+62,255
+18% +$1.04M 0.17% 69
2019
Q3 		$5.2M Buy
349,625
+35,247
+11% +$475K 0.11% 73
2019
Q2 		$5.2M Buy
314,378
+28,616
+10% +$467K 0.13% 73
2019
Q1 		$4.94M Buy
+285,762
New +$5.19M 0.14% 69

Other funds holding CBMG

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Man Group
Man Group London, United Kingdom $55.1B AUM 24.23% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

ARK Investment Management's CBMG Position: Q4 2020 in Review

ARK Investment Management sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q4 2020, closing a stake of 71,010 shares — an estimated $1.3M sold.

ARK Investment Management first reported a position in CBMG in Q1 2019 and held it in 7 quarters. The position peaked at $9.01M in Q2 2020. 67 funds tracked by Wall St. Rank hold CBMG as of Q4 2020.

  • ARK Investment Management reported no remaining Cellular Biomedicine Group, Inc. position as of Q4 2020 after selling out during the quarter.
  • ARK Investment Management sold 71,010 Cellular Biomedicine Group, Inc. shares in Q4 2020, an estimated $1.3M.
  • ARK Investment Management first reported a position in Cellular Biomedicine Group, Inc. in Q1 2019 and held it in 7 quarters.
  • ARK Investment Management's Cellular Biomedicine Group, Inc. position peaked at $9.01M in Q2 2020.
  • 67 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q4 2020.

Based on ARK Investment Management's 13F filing for Q4 2020, filed 12 Feb 2021.